Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.

Cardiology research and practice

Amin AM, Sheau Chin L, Azri Mohamed Noor D, Sk Abdul Kader MA, Kah Hay Y, Ibrahim B.
PMID: 28421156
Cardiol Res Pract. 2017;2017:8062796. doi: 10.1155/2017/8062796. Epub 2017 Mar 21.

Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular events. Although many genetic and nongenetic factors...

Cite
Amin AM, Sheau Chin L, Azri Mohamed Noor D, et al. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiol Res Pract. 2017;2017:8062796doi: 10.1155/2017/8062796.
Amin, A. M., Sheau Chin, L., Azri Mohamed Noor, D., Sk Abdul Kader, M. A., Kah Hay, Y., & Ibrahim, B. (2017). The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiology research and practice, 20178062796. https://doi.org/10.1155/2017/8062796
Amin, Arwa M, et al. "The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics." Cardiology research and practice vol. 2017 (2017): 8062796. doi: https://doi.org/10.1155/2017/8062796
Amin AM, Sheau Chin L, Azri Mohamed Noor D, Sk Abdul Kader MA, Kah Hay Y, Ibrahim B. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiol Res Pract. 2017;2017:8062796. doi: 10.1155/2017/8062796. Epub 2017 Mar 21. PMID: 28421156; PMCID: PMC5379098.
Copy Download .nbib Format: NLM
Coronary Heart Disease (CHD) in Elderly Patients: Which Drug to Choose, Ticagrelor and Clopidogrel? A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of cardiovascular development and disease

Akkaif MA, Sha'aban A, Daud NAA, Yunusa I, Ng ML, Sk Abdul Kader MA, Noor DAM, Ibrahim B.
PMID: 34677192
J Cardiovasc Dev Dis. 2021 Sep 30;8(10). doi: 10.3390/jcdd8100123.

BACKGROUND: A new generation P2Y12 receptor inhibitor (ticagrelor) is recommended in current therapeutic guidelines to treat patients with coronary heart disease (CHD). However, it is unknown if ticagrelor is more effective than clopidogrel in elderly patients. Therefore, a systematic...

Cite
Akkaif MA, Sha'aban A, Daud NAA, et al. Coronary Heart Disease (CHD) in Elderly Patients: Which Drug to Choose, Ticagrelor and Clopidogrel? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Dev Dis. 2021;8(10)doi: 10.3390/jcdd8100123.
Akkaif, M. A., Sha'aban, A., Daud, N. A. A., Yunusa, I., Ng, M. L., Sk Abdul Kader, M. A., Noor, D. A. M., & Ibrahim, B. (2021). Coronary Heart Disease (CHD) in Elderly Patients: Which Drug to Choose, Ticagrelor and Clopidogrel? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of cardiovascular development and disease, 8(10), . https://doi.org/10.3390/jcdd8100123
Akkaif, Mohammed Ahmed, et al. "Coronary Heart Disease (CHD) in Elderly Patients: Which Drug to Choose, Ticagrelor and Clopidogrel? A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Journal of cardiovascular development and disease vol. 8,10 (2021). doi: https://doi.org/10.3390/jcdd8100123
Akkaif MA, Sha'aban A, Daud NAA, Yunusa I, Ng ML, Sk Abdul Kader MA, Noor DAM, Ibrahim B. Coronary Heart Disease (CHD) in Elderly Patients: Which Drug to Choose, Ticagrelor and Clopidogrel? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Dev Dis. 2021 Sep 30;8(10). doi: 10.3390/jcdd8100123. PMID: 34677192; PMCID: PMC8538993.
Copy Download .nbib Format: NLM
A review of the effects of ticagrelor on adenosine concentration and its clinical significance.

Pharmacological reports : PR

Akkaif MA, Ng ML, Sk Abdul Kader MA, Daud NAA, Sha'aban A, Ibrahim B.
PMID: 34283374
Pharmacol Rep. 2021 Dec;73(6):1551-1564. doi: 10.1007/s43440-021-00309-0. Epub 2021 Jul 20.

BACKGROUND: Ticagrelor is an oral antiplatelet drug that can reversibly bind to the platelet P2Y12 receptor. Ticagrelor is metabolized mainly by CYP3A4 and produces a rapid blood concentration-dependent platelet inhibitory effect. Unlike other P2Y12 receptor antagonists, many clinical features...

Cite
Akkaif MA, Ng ML, Sk Abdul Kader MA, et al. A review of the effects of ticagrelor on adenosine concentration and its clinical significance. Pharmacol Rep. 2021;73(6):1551-1564doi: 10.1007/s43440-021-00309-0.
Akkaif, M. A., Ng, M. L., Sk Abdul Kader, M. A., Daud, N. A. A., Sha'aban, A., & Ibrahim, B. (2021). A review of the effects of ticagrelor on adenosine concentration and its clinical significance. Pharmacological reports : PR, 73(6), 1551-1564. https://doi.org/10.1007/s43440-021-00309-0
Akkaif, Mohammed Ahmed, et al. "A review of the effects of ticagrelor on adenosine concentration and its clinical significance." Pharmacological reports : PR vol. 73,6 (2021): 1551-1564. doi: https://doi.org/10.1007/s43440-021-00309-0
Akkaif MA, Ng ML, Sk Abdul Kader MA, Daud NAA, Sha'aban A, Ibrahim B. A review of the effects of ticagrelor on adenosine concentration and its clinical significance. Pharmacol Rep. 2021 Dec;73(6):1551-1564. doi: 10.1007/s43440-021-00309-0. Epub 2021 Jul 20. PMID: 34283374.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries